1,892,050 Shares in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Purchased by Trium Capital LLP

Trium Capital LLP purchased a new position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 1,892,050 shares of the biotechnology company’s stock, valued at approximately $2,081,000. Trium Capital LLP owned about 2.66% of Aclaris Therapeutics as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the stock. Bain Capital Life Sciences Investors LLC boosted its stake in Aclaris Therapeutics by 2.9% in the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 3,500,000 shares of the biotechnology company’s stock worth $3,675,000 after purchasing an additional 100,000 shares in the last quarter. Octagon Capital Advisors LP bought a new position in Aclaris Therapeutics in the 4th quarter valued at approximately $105,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Aclaris Therapeutics in the 1st quarter worth $39,000. BNP Paribas Financial Markets raised its stake in shares of Aclaris Therapeutics by 10.9% in the first quarter. BNP Paribas Financial Markets now owns 241,101 shares of the biotechnology company’s stock worth $299,000 after purchasing an additional 23,747 shares during the last quarter. Finally, Deuterium Capital Management LLC bought a new position in shares of Aclaris Therapeutics during the first quarter valued at $99,000. Hedge funds and other institutional investors own 98.34% of the company’s stock.

Insiders Place Their Bets

In related news, major shareholder Braden Michael Leonard acquired 528,621 shares of the business’s stock in a transaction that occurred on Thursday, June 13th. The stock was bought at an average cost of $1.15 per share, for a total transaction of $607,914.15. Following the purchase, the insider now owns 11,007,134 shares in the company, valued at approximately $12,658,204.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders purchased a total of 2,609,123 shares of company stock worth $2,976,646 over the last quarter. 6.40% of the stock is currently owned by corporate insiders.

Aclaris Therapeutics Stock Down 0.8 %

NASDAQ ACRS opened at $1.17 on Monday. The company has a 50-day moving average price of $1.24 and a 200-day moving average price of $1.21. Aclaris Therapeutics, Inc. has a 52 week low of $0.59 and a 52 week high of $8.28. The firm has a market capitalization of $83.38 million, a P/E ratio of -1.07 and a beta of 0.21.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.04. Aclaris Therapeutics had a negative net margin of 183.28% and a negative return on equity of 53.18%. The business had revenue of $2.77 million for the quarter, compared to analysts’ expectations of $1.74 million. As a group, equities research analysts anticipate that Aclaris Therapeutics, Inc. will post -0.66 EPS for the current year.

Wall Street Analysts Forecast Growth

ACRS has been the subject of several research analyst reports. HC Wainwright reiterated a “neutral” rating on shares of Aclaris Therapeutics in a report on Monday, August 19th. StockNews.com raised shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, July 25th. Seven investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $22.25.

Aclaris Therapeutics Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.